Launched renal anemia treatment NESP® Injection 5μg Plastic Syringe in Japan
February
Added new information covering pollinosis mechanisms and sublingual immunotherapy to the pollen information website, Pollinosis Navi
Received approval for additional dosage and administration indication for calcium receptor agonist REGPARA® Tablets 25mg and 75mg in Japan
March
Began construction of new research building IK8 at Fuji Research Park
Received approval for additional indication for anti-CCR4 humanized antibody POTELIGEO® for relapsed or refractory CCR4-positive peripheral T-cell lymphoma in Japan and cutaneous T-cell lymphoma in Japan
Started second season of web cartoon “New Antibody Story,” which explains the mechanisms of antibodies and immunity
Kyowa Hakko Bio received 2014 JSBBA* Award for Achievement in Technological Research for developing and commercializing dipeptide fermentation technology
*JSBBA: Japan Society for Bioscience, Biotechnology, and Agrochemistry
April
Consolidated and reorganized the research and development divisions
Completed construction of the HA4 Plant, a biopharmaceutical API manufacturing facility, at the Takasaki Plant
Held the Kyowa Hakko Kirin Cup and fourth WASURENAI 3.11 Kizuna Four-Prefecture (Iwate, Miyagi, Ibaraki, Fukushima) Table Tennis Tournament. Set Guinness World Record® for most participants in a table tennis rally.
May
Launched a new formulation of Topina® (Topina® Fine Granules 10%), an antiepileptic agent in Japan
June
Received approval for additional indication of chronic pain for Fentos® , a transdermal longacting pain relief patch in Japan
July
Sakai Plant was awarded a Prime Minister’s Commendation on Contributors to Public Safety
Concluded development alliance with AstraZeneca of the United Kingdom for cancer immunotherapy from the initial development phase
Signed domestic sales outsourcing agreement with Japan Blood Products Organization for recombinant human antithrombin preparation KW-3357
Kyowa Medex launched “A1c iGear K,” glycated hemoglobin analysis equipment for diabetes testing in Japan
Submitted application for approval in Japan for recombinant human antithrombin preparation KW-3357
August
ProStrakan Group plc of the United Kingdom acquired Archimedes Pharma Limited of the United Kingdom
September
Launched Dovobet® , a treatment for psoriasis vulgaris in Japan
Concluded development alliance with Pfizer Inc. of the United States for cancer immunotherapy from the initial development phase
October
Initiated phase I trial for KHK6640 for Alzheimer’s disease in Europe
Completed construction of the HA5 Plant, a drug product manufacturing facility, at the Takasaki Plant
November
Kyowa Hakko Bio launched renewal of the supplement “Fermented Coenzyme Q10 EX” in Japan
Added ITP Consultation Room, where medical specialists answer questions, to the ITP website
Launched sustained-duration G-CSF product G-Lasta® in Japan
December
Concluded development alliance with ONO PHARMACEUTICAL CO., LTD. of Japan and Bristol-Myers Squibb Company of the United States for cancer immunotherapy from the initial development phase
Received approval for additional indication of NESP® for anemia with myelodysplastic syndrome in Japan
Received approval for additional indication of the anti-CCR4 humanized antibody POTELIGEO® for chemotherapy-native CCR4-positive ATL in Japan
Concluded exclusive license agreement with Syndax Pharmaceuticals, Inc. of the United States to develop and commercialize Entinostat in Japan and Korea
